TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05679037

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid 600 MG Oral Capsule
Description: Universal antioxidant
Study: NCT05263960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM350_group 1
Description: CM350 will be administered intravenously (IV) once a week (QW). Patients will take 5ug of CM350 on the first day of first cycle (C1D1), 5ug on C1D8, 5ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT05347498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR091506 tablets + placebo of febuxostat tablets
Description: HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: febuxostat tablets + placebo of HR091506 tablets
Description: febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
Study: NCT06570161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEEUS95 Transparent mask
Description: SEEUS95 developed transparent filtering mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CrystalGuard Mask
Description: CrystalGuard transparent mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 face mask
Description: Standard N95 style face mask
Study: NCT05569317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: primary nursing
Description: The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
Study: NCT05079269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: As above
Study: NCT05032937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domestic polysaccharide superparamagnetic iron oxide nanoparticle
Description: Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
Study: NCT06345560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: 4 mg tablet once daily
Study: NCT04814043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
Study: NCT05997199

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D replacement
Description: Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
Study: NCT05426863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DeVI
Description: A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
Study: NCT05907551

Intervention type: OTHER
Intervention: Questionnaires
Description: 25-items questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: 25-items questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: 25-items questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: 25-items questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: 25-items questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: 25-items questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: 25-items questionnaire
Study: NCT04465734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
Study: NCT05607953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 doses are administered via PRVI using the PEDD method of administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD-1
Description: In the Phase 1b, anti-PD-1 will be administered together with SD-101
Study: NCT06374732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: The experimental group will perform 6-to-10-minute of high-intensity interval training at the beginning of their physical education lessons or physical activity lessons.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will maintain their normal behaviour, including regular physical education lessons and physical activity lessons.
Study: NCT05685524

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation test
Description: Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation test
Description: Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
Study: NCT05154552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises
Study: NCT05044728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody combined with Paclitaxel and carboplatin.
Description: Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.~Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment stage
Description: After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
Study: NCT04629599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for major depression following perinatal loss
Description: Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with Depression
Description: The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
Study: NCT06232239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin-Test product
Description: Empagliflozin 10 mg tablets Test product Manufactured by: Thai Meiji Pharmaceuticals Co., Ltd., Thailand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin-Reference product
Description: Empagliflozin 10 mg tablets Reference product Manufactured by: Boehringer Ingelheim Pharma Gmbh \& Co. Kg, Germany
Study: NCT05296876

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy (CEA)
Description: Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
Study: NCT06045520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information-Motivation-Behavioral Skills Model
Description: 1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
Study: NCT05594680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 50 MG
Study: NCT05455268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHOPE
Description: e-Haematological Oncology Parents Education (eHOPE) consists of caregiving information for parents of children with leukaemia and lymphoma, presented in multimedia format through an online learning platform. The contents are developed in Malay language, encompassing basic information on disease and treatment, medical caregiving, emotional caregiving, appraising information, communication and self-care. Parents will be able to access multimedia information designed to support them in the care of their sick child. There are 4 self-paced activities in eHOPE with the following objectives:~1. Parents should be able to outline key tasks related to care for their child at home.~2. Parents should be able to outline strategies to initiate discussions with their child's healthcare providers.~3. Parents should be able to appraise reliability of information sources.~4. Parents should be able to identify coping strategies that they can use when faced with stressful situations.
Study: NCT05594680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06758882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: administration of non steroid androgenic receptor inhibitors plus androgen deprivation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen receptor (AR) inhibitor
Description: administration of androgen deprivation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) inhibitor
Description: administration of androgen deprivation therapy
Study: NCT06758635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRET-O Group
Description: Arm Description: the participants of this group will get 3 hours lasting online single session VR therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: VRET-O Group
Description: Arm Description: the participants of this group will get 3 hours lasting online single session VR therapy
Study: NCT05393336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V-sitting posture stabilization
Description: 15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the V-sitting exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified clamshell exercises
Description: 15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the modified clamshell exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
Study: NCT05135013

Intervention type: DRUG
Intervention: Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
Description: History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration
Study: NCT06758635

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Flash-O Group
Description: Arm Description: the participants of this group will get 3 hours lasting online single session EMDR Flash therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flash-O Group
Description: Arm Description: the participants of this group will get 3 hours lasting online single session EMDR Flash therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PYSCHOEDU-O Group
Description: Arm Description: the participants of this group will get 1 hour lasting online psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PYSCHOEDU-O Group
Description: Arm Description: the participants of this group will get 1 hour lasting online psychotherapy
Study: NCT06759129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate-use of a mobile health application until completion
Description: Participants will use the RomSi app for approximately 14 days, completing all scheduled activities. Throughout the intervention, they will respond to ecological momentary assessments (EMA) designed to evaluate stigma, help-seeking intentions, and suicidal ideation.~The activities within the app will include interactive games aimed at fostering empathy and emotional understanding. Participants will also have continuous access to specialized help contacts to ensure their well-being during the study.~The protocol involves two groups that will receive tailored information based on their specific needs:~1. Individuals with low suicidal ideation and/or self-stigma, who will engage in activities focused on reducing personal stigma.~2. Individuals experiencing suicide bereavement, who will receive support tailored to address their loss and foster resilience.~A follow-up will be carried out one month and three months after the end of the intervention.
Study: NCT04935060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A guide to inform the process of delivering the outcomes of a dementia assessment
Description: The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Clinicians conduct the dementia assessment as per standard protocols
Study: NCT06759129

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed use of a mobile health application until completion
Description: Participants assigned to the dApp group (delayed use) will not have access to the RomSi app during the first two weeks of the study. During this period, they will complete ecological momentary assessments (EMA) to evaluate stigma, help-seeking intentions, and suicidal ideation, without engaging in the intervention activities associated with the app.~After completing this initial control phase, participants in the dAPP group will begin using the RomSi app, following the same protocol as the iAPP group. This includes interactive activities, such as games designed to foster empathy and understanding, along with continuous access to specialized help contacts.~This crossover design allows for the immediate effects of the intervention to be compared between groups, while also evaluating changes in pre- and post-intervention measures across both conditions.~A follow-up will be carried out one month and three months after the end of the intervention.
Study: NCT06759181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-BCMA/FcRL5 CAR T
Description: anti-BCMA/FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.~Other Name:
Study: NCT06759402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family based treatment
Description: FBT is an intensive, manualized therapy in which the parents of those affected are closely involved in a resource-oriented manner by FBT-certified therapists. FBT takes place in 3 phases: in phase 1, the parents take responsibility for their child's weight gain. Phase 2 involves the gradual transfer of responsibility for eating back to the patient. Phase 3 focuses on individual issues of the children and adolescents, e.g. catching up on important developmental steps missed due to the illness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient multimodal therapy
Description: comprehensive, patient-oriented and multidisciplinary approach to address eating disorders following the S3 joint German treatment guidelines in specialized hospitals. Includes individual psychotherapy, family sessions, body-oriented therapy, nutritional counseling, group therapy sessions, relaxation techniques, mindfulness practices, and skills training. Targeted weight gain per week is at least 500g.
Study: NCT06759298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: patient group will recieve methylphenidate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo tablet
Description: placebo gtoup will recieve matched placebo tablet